<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270045" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39712904</article-id><article-id pub-id-type="pmc">PMC11662988</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70045</article-id><article-id pub-id-type="publisher-id">DEO270045</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Feasibility of non&#x02010;anesthesiologist&#x02010;administered sedation with dexmedetomidine and midazolam during endoscopic submucosal dissection of upper gastrointestinal tumors</article-title><alt-title alt-title-type="left-running-head">ISHIDO <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270045-cr-0001" contrib-type="author" corresp="yes"><name><surname>Ishido</surname><given-names>Kenji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6434-2902</contrib-id><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>k.ishido@kitasato-u.ac.jp</email></address></contrib><contrib id="deo270045-cr-0002" contrib-type="author"><name><surname>Tanabe</surname><given-names>Satoshi</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270045-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270045-cr-0003" contrib-type="author"><name><surname>Kitahara</surname><given-names>Gen</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270045-cr-0004" contrib-type="author"><name><surname>Furue</surname><given-names>Yasuaki</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270045-cr-0005" contrib-type="author"><name><surname>Wada</surname><given-names>Takuya</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270045-cr-0006" contrib-type="author"><name><surname>Watanabe</surname><given-names>Akinori</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270045-cr-0007" contrib-type="author"><name><surname>Matsuda</surname><given-names>Hiromi</given-names></name><xref rid="deo270045-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270045-cr-0008" contrib-type="author"><name><surname>Okamoto</surname><given-names>Hirotsugu</given-names></name><xref rid="deo270045-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270045-cr-0009" contrib-type="author"><name><surname>Kusano</surname><given-names>Chika</given-names></name><xref rid="deo270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270045-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Kitasato University School of Medicine</institution>
<city>Kanagawa</city>
<country country="JP">Japan</country>
</aff><aff id="deo270045-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Anesthesiology</named-content>
<institution>Kitasato University School of Medicine</institution>
<city>Kanagawa</city>
<country country="JP">Japan</country>
</aff><aff id="deo270045-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Ebina General Hospital</institution>
<city>Kanagawa</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Kenji Ishido, Department of Gastroenterology, Kitasato University School of Medicine, 1&#x02010;15&#x02010;1 Kitasato, Minami&#x02010;ku, Sagamihara, Kanagawa 252&#x02010;0374, Japan.<break/> Email: <email>k.ishido@kitasato-u.ac.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="50">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70045</elocation-id><history>
<date date-type="received"><day>08</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>29</day><month>11</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70045.pdf"/><abstract><title>Abstract</title><sec id="deo270045-sec-0010"><title>Objectives</title><p>The efficacy and safety of a sedation regimen combining dexmedetomidine and midazolam during endoscopic submucosal dissection for upper gastrointestinal tumors remains unclear. In this study, we aimed to evaluate the efficacy and safety of this sedation regimen, where non&#x02010;anesthesiologists performed sedation.</p></sec><sec id="deo270045-sec-0020"><title>Methods</title><p>Sixty&#x02010;eight patients who underwent endoscopic submucosal dissection for upper gastrointestinal tumors, sedated by non&#x02010;anesthesiologists, were retrospectively evaluated. The sedation was performed by non&#x02010;anesthesiologists as part of on&#x02010;the&#x02010;job training (OJT) under anesthesiologists' supervision. Each non&#x02010;anesthesiologist received OJT at least thrice. Proficiency levels were assessed during the third OJT session. The target sedation depth was a Richmond Agitation&#x02010;Sedation Scale of &#x02212;2 to &#x02212;4, with 2 L/min of oxygen delivered via a nasal cannula at sedation initiation. The treatment completion rates, which measured efficacy and safety, were assessed by the frequencies of respiratory depression, hypotension, and bradycardia.</p></sec><sec id="deo270045-sec-0030"><title>Results</title><p>The study included 14, 52, and two patients with superficial esophageal cancer, early gastric cancer, and gastric adenoma, respectively. The median treatment time was 68 and 84&#x000a0;min for superficial esophageal cancer, early gastric cancer, and adenoma, respectively. Endoscopic submucosal dissection was completed in all patients. No severe sedation&#x02010;related adverse events were reported; however, peripheral arterial oxygen saturation &#x0003c;90%, hypotension, and bradycardia occurred in 1 (1.5%), 30 (44.1%), and 30 patients (44.1%), respectively. All 22 non&#x02010;anesthesiologists who underwent the proficiency evaluation passed the test.</p></sec><sec id="deo270045-sec-0040"><title>Conclusions</title><p>A sedation regimen combining dexmedetomidine and midazolam can be feasibly administered by non&#x02010;anesthesiologists. Further studies are needed to verify the effectiveness of OJT.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270045-kwd-0001">dexmedetomidine</kwd><kwd id="deo270045-kwd-0002">endoscopic submucosal dissection</kwd><kwd id="deo270045-kwd-0003">non&#x02010;anesthesiologist</kwd><kwd id="deo270045-kwd-0004">on&#x02010;the&#x02010;job training</kwd><kwd id="deo270045-kwd-0005">sedation</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="6"/><page-count count="10"/><word-count count="4579"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270045-sec-0050"><title>INTRODUCTION</title><p>The role of sedation in endoscopic procedures is to alleviate patient anxiety and distress, thereby improving patient acceptance and satisfaction.<xref rid="deo270045-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Sedation during these endoscopic procedures can cause airway compression by the endoscope, necessitating close monitoring of respiration. Data from the American Society of Anesthesiologists Closed Claims database suggest that sedation outside the operating room due to oversedation and inadequate oxygenation or ventilation during monitored anesthesia care poses significant risks.<xref rid="deo270045-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>In Japan, there is a shortage of anesthesiologists, making it difficult for them to oversee all sedation procedures.<xref rid="deo270045-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Consequently, non&#x02010;anesthesiologists, particularly gastroenterologists, often manage the sedation of patients despite having little training in this area. These patients frequently require prolonged treatment or have higher sedation related&#x02010;risks (Table&#x000a0;<xref rid="deo270045-tbl-0001" ref-type="table">1</xref>). Therefore, a system to support safe sedation is required to ensure patient safety.<xref rid="deo270045-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270045-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><table-wrap position="float" id="deo270045-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Reasons for sedation problems when administered by non&#x02010;anesthesiologists (gastroenterologists).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody><tr><td align="left" rowspan="1" colspan="1">The issue of the need for sedation</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="deo270045-list-0001"><list-item><p>Improved diagnosis of early&#x02010;stage cancer has increased the need for sedation during endoscopy and treatment.</p></list-item><list-item><p>Diversification of sedation agents.</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">A matter of recognition</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="deo270045-list-0002"><list-item><p>Lack of awareness that sedation improves the quality of examination and treatment but may compromise patient safety.</p></list-item><list-item><p>Difference between sedation and general anesthesia.</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Training system issues</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="deo270045-list-0003"><list-item><p>Non&#x02010;anesthesiologists (particularly gastroenterologists) often receive little training in sedation.</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Anesthesiologist issues</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="deo270045-list-0004"><list-item><p>Lack of manpower of anesthesiologists in Japan.</p></list-item></list>
</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>At our hospital, midazolam (MDZ) or propofol is commonly used for sedation during endoscopic procedures. However, propofol has a narrow therapeutic range and carries risks of respiratory depression and circulatory instability.<xref rid="deo270045-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Recently, dexmedetomidine (DEX, Maruishi Pharmaceutical Co., Ltd.) has been approved for use under insurance coverage for &#x0201c;sedation during non&#x02010;intubated surgery and procedures under local anesthesia,&#x0201d; and is now widely used as a sedative during endoscopic procedures.</p><p>Sedation using a combination of DEX and MDZ for endoscopic retrograde cholangiopancreatography is reportedly feasible in adults aged &#x0003e;80 years when administered by non&#x02010;anesthesiologists.<xref rid="deo270045-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> However, the use of DEX for sedation in our hospital during endoscopic procedures was restricted due to safety concerns related to cardiac dynamics.</p><p>To safely implement a sedation regimen combining DEX and MDZ for endoscopic submucosal dissection (ESD) of upper gastrointestinal tumors, we introduced a sedation licensing system for non&#x02010;anesthesiologists. This program consists of a web&#x02010;based training course, on&#x02010;the&#x02010;job training (OJT) for a minimum of three sessions per physician under anesthesiologist supervision, and a proficiency evaluation during the third OJT session. Only non&#x02010;anesthesiologists who pass the sedation licensing system were allowed to use the combined DEX and MDZ sedation regimen in practice.</p><p>We retrospectively evaluated the efficacy and safety of a sedation regimen administered by non&#x02010;anesthesiologists in patients undergoing ESD for upper gastrointestinal tumors.</p></sec><sec id="deo270045-sec-0060"><title>METHODS</title><sec id="deo270045-sec-0070"><title>Patients</title><p>We retrospectively examined the efficacy and safety of a sedation regimen in consecutive ESD cases for upper gastrointestinal tumors. Sedation in these cases was administered by a non&#x02010;anesthesiologist under OJT using the sedation regimen of DEX and MDZ in the Department of Gastroenterology at Kitasato University School of Medicine, between January 2021 and August 2023. The OJT was conducted under the supervision of an anesthesiologist, with sedation performed by personnel separate from the endoscopist conducting the procedure. Cases without complete proficiency assessments for the first, second, and third OJT sessions were excluded.</p><p>The clinicopathological characteristics of the patients included age, sex, body mass index (BMI), Eastern Cooperative Oncology Group performance status, American Society of Anesthesiologists physical status classification (ASA&#x02010;PS),<xref rid="deo270045-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Charlson Comorbidity Index,<xref rid="deo270045-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> presence of cardiovascular or respiratory disease, use of antithrombotic medication, smoking history (categorized as never/light [&#x0003c;30 pack&#x02010;years] or heavy [&#x02265;30 pack&#x02010;years]), alcohol consumption (categorized as never, current drinker, or existing drinker) and pure ethanol equivalent, lesion site (upper, middle, or lower thoracic esophagus, and upper, middle, lower, or remnant stomach), macroscopic type (protruded or flat and depressed), presence of scarring, histological type (squamous cell carcinoma, adenocarcinoma, or other in esophagus; differentiated or undifferentiated in the stomach), diameter of the resected specimen (mm), diameter of the resected tumor (mm), depth of invasion, complete en bloc resection, curability criteria for endoscopic resection in the stomach,<xref rid="deo270045-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> and treatment duration. Treatment duration was defined as the time from insertion to removal of the endoscope. Adverse events were evaluated using Common Terminology Criteria for Adverse Events Version 5.0.<xref rid="deo270045-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Delayed bleeding was defined as &#x0201c;hematemesis or hemorrhage&#x0201d; or &#x0201c;Hb &#x0003c;2&#x000a0;g/dL,&#x0201d; with endoscopically confirmed bleeding within 28 days post&#x02010;ESD. Perforation was defined by the absence of muscularis propria and the presence of intra&#x02010;abdominal free air or mediastinal emphysema.</p><p>Procedure availability was assessed based on the occurrence of body movements during upper ESD that interrupted treatment. Safety was evaluated by the frequency of respiratory depression (percutaneous peripheral arterial oxygen saturation [SpO<sub>2</sub>] &#x0003c;90% or the need for nasal airway insertion), hypotension (systolic blood pressure &#x0003c;90&#x000a0;mmHg), and bradycardia (pulse &#x0003c;50&#x000a0;bpm).</p><p>Informed consent, with an opt&#x02010;out option, was obtained from all patients in compliance with the Japanese guidelines for human medical research. This study adhered to the principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the Kitasato University School of Medicine Hospital (B21&#x02010;207).</p></sec><sec id="deo270045-sec-0080"><title>Sedation licensing system</title><p>OJT for non&#x02010;anesthesiologists is part of the sedation licensing system, which consists of the following steps (Figure&#x000a0;<xref rid="deo270045-fig-0001" ref-type="fig">1</xref>):</p><fig position="float" fig-type="FIGURE" id="deo270045-fig-0001"><label>FIGURE 1</label><caption><p>Sedation Licensing System</p></caption><graphic xlink:href="DEO2-5-e70045-g001" position="anchor" id="jats-graphic-1"/></fig><p>1) Non&#x02010;anesthesiologists attended a web&#x02010;based training course on sedation and analgesia provided by anesthesiologists. The course covered the purpose of sedation, target sedation depth, pharmacologic actions of sedatives and analgesics, mechanism of action, contraindications, administration methods, antagonists, and response to emergencies. After the training session, a confirmatory test was administered, and a score of &#x02265;60 out of 100 points was considered acceptable.</p><p>2) Non&#x02010;anesthesiologists who passed the web&#x02010;based training session were administered OJT at least three times per physician using the sedation regimen prepared by the anesthesiologist.</p><p>Initially, the anesthesiologist provided detailed instructions according to the &#x0201c;Flowchart for sedation regimen,&#x0201d; such as adjustments to DEX dosage or additional doses of buprenorphine hydrochloride (BPN; Table&#x000a0;<xref rid="deo270045-tbl-0002" ref-type="table">2</xref>). In the second OJT session, a non&#x02010;anesthesiologist primarily managed sedation, with guidance provided as needed. By the third session, non&#x02010;anesthesiologists almost exclusively managed sedation and were evaluated by the anesthesiologist on a 5&#x02010;point scale across 11 items (Table&#x000a0;<xref rid="deo270045-tbl-0003" ref-type="table">3</xref>). Passing was determined by achieving a mean score of &#x02265;4.0, with no individual score &#x0003c;2 in each category.</p><table-wrap position="float" id="deo270045-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Flowchart for the sedation regimen with dexmedetomidine and midazolam.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><tbody><tr><td align="left" rowspan="7" colspan="1">Routine work</td><td align="left" rowspan="1" colspan="1">DEX loading</td><td align="left" rowspan="1" colspan="1">&#x02265;80 years</td><td align="left" rowspan="1" colspan="1">DEX loading at 6&#x000a0;&#x000b5;g/kg/h for 5&#x000a0;min, continuous administration of DEX at 0.4&#x000a0;&#x000b5;g/kg/h</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;80 years</td><td align="left" rowspan="1" colspan="1">DEX loading at 6&#x000a0;&#x000b5;g/kg/h for 10&#x000a0;min, continuous administration of DEX at 0.4&#x000a0;&#x000b5;g/kg/h</td></tr><tr><td align="left" rowspan="1" colspan="1">DEX maintenance dose</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DEX 0.4&#x000a0;&#x000b5;g/kg/h of continuous administration</td></tr><tr><td align="left" rowspan="2" colspan="1">
<p>(Initial dose)</p>
<p>Midazolam and buprenorphine hydrochloride</p>
</td><td align="left" rowspan="1" colspan="1">&#x02265;60 years</td><td align="left" rowspan="1" colspan="1">Midazolam 1&#x000a0;mg i.v. and buprenorphine hydrochloride 0.1&#x000a0;mg i.v.</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;60 years</td><td align="left" rowspan="1" colspan="1">Midazolam 2&#x000a0;mg i.v. and buprenorphine hydrochloride 0.2&#x000a0;mg i.v.</td></tr><tr><td align="left" rowspan="1" colspan="1">When inserting an overtube</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Additional doses of buprenorphine hydrochloride 0.1&#x000a0;mg i.v.</td></tr><tr><td align="left" rowspan="1" colspan="1">More than 90&#x000a0;min after the first dose</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Additional doses of buprenorphine hydrochloride 0.1&#x000a0;mg i.v.</td></tr><tr><td align="left" rowspan="10" colspan="1">Improvised work</td><td align="left" rowspan="2" colspan="1">During body movement</td><td align="left" rowspan="1" colspan="1">&#x02265;60 years</td><td align="left" rowspan="1" colspan="1">Midazolam 1&#x000a0;mg i.v. and DEX increased each by 0.1&#x000a0;&#x000b5;g/kg/h (up to 0.7&#x000a0;&#x000b5;g/kg/h)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;60 years</td><td align="left" rowspan="1" colspan="1">Midazolam 2&#x000a0;mg iv and DEX increased each by 0.1&#x000a0;&#x000b5;g/kg/h (up to 0.7&#x000a0;&#x000b5;g/kg/h)</td></tr><tr><td align="left" rowspan="1" colspan="1">During severe body movements that are uncontrollable by one person</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Additional doses of buprenorphine hydrochloride 0.1&#x000a0;mg i.v.; administration 5&#x000a0;min apart, up to two consecutive doses</td></tr><tr><td align="left" rowspan="1" colspan="1">The total dose of midazolam exceeds 5&#x000a0;mg, and the upper limit of DEX (0.7 ug/kg/h)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Additional doses of buprenorphine hydrochloride 0.1&#x000a0;mg i.v.</p>
<p>Can be administered as many times as needed, 20&#x000a0;min apart</p>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Adjustment of DEX</td><td align="left" rowspan="1" colspan="1">Tachycardia (e.g., &#x0003e;80 beats per min [bpm]) and sufficient blood pressure (e.g., 140&#x000a0;mmHg)</td><td align="left" rowspan="1" colspan="1">DEX increased each by 0.1&#x000a0;&#x000b5;g/kg/h (up to 0.7&#x000a0;&#x000b5;g/kg/h)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bradycardia (e.g., &#x0003c;40&#x000a0;bpm sustained and blood pressure &#x0003c;100&#x000a0;mmHg)</td><td align="left" rowspan="1" colspan="1">DEX decreased each by 0.1&#x000a0;&#x000b5;g/kg/h</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate in the range of 40 bpm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DEX decreased each by 0.1&#x000a0;&#x000b5;g/kg/h, or administration of ephedrine hydrochloride 4&#x000a0;mg i.v. or atropine sulfate 0.5&#x000a0;mg i.v.</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure &#x0003c;80 mmHg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Administer ephedrine hydrochloride 4&#x000a0;mg i.v. It can be administered as many times as needed, 5&#x000a0;min apart.</td></tr><tr><td align="left" rowspan="1" colspan="1">Airway obstruction</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Perform airway clearance, such as mandibular elevation and insertion of the nasal airway tube. If there is no improvement, decrease dexmedetomidine.</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory arrest</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DEX is stopped, and the breathing is supported until the call response is made.</td></tr></tbody></table><table-wrap-foot><fn id="deo270045-tbl2-note-0001"><p>Abbreviations: DEX, dexmedetomidine; i.v., intravenous injection.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270045-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Evaluation items of on&#x02010;the&#x02010;job training.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Evaluation details</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Loading</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Age&#x02010;appropriate drug adjustment</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Coping with body movement</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Adjustment of DEX maintenance rate</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Additional dose of buprenorphine hydrochloride</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Airway management</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Circulation management</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Vital sign check</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Check the sedation level</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Timing of return to the room</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Instructions for returning to the room</td></tr></tbody></table><table-wrap-foot><fn id="deo270045-tbl3-note-0001"><p>
<italic toggle="yes">Notes</italic>: &#x0201c;The evaluation contents are rated on a 5&#x02010;point scale.&#x0201d;</p></fn><fn id="deo270045-tbl3-note-0002"><p>1: All are poorly understood; 2: Partially understood but not fully; 3: I can understand and act if pointed out; 4: I can make decisions on my own initiative with my own criteria; 5: Accurate knowledge and the ability to act safely.</p></fn><fn id="deo270045-tbl3-note-0003"><p>OJT pass criteria: On evaluation after the third session, an average of &#x02265;4.0 points with no items &#x0003c;2 points.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>To obtain sedation licensure, participants were required to complete web&#x02010;based training, OJT, and resuscitation training. An anesthesiologist assessed whether a non&#x02010;anesthesiologist could safely administer sedation independently. Following this evaluation, the anesthesiologist reviewed the OJT scores and provided feedback.</p><p>The third OJT session required a mandatory evaluation by the anesthesiologist, whereas evaluation for the first and second sessions was optional.</p></sec><sec id="deo270045-sec-0090"><title>Sedation regimen</title><p>The sedation regimen was developed by an anesthesiologist who visited the endoscopy center and adapted it to the actual conditions of the endoscopic procedures.</p><p>DEX was initiated at a continuous infusion rate of 6&#x000a0;&#x000b5;g/kg/h as a loading dose. The loading time for DEX was 10&#x000a0;min for patients aged &#x0003c;80 years and 5&#x000a0;min for those aged &#x02265;80 years. Subsequently, the DEX infusion was reduced to a maintenance dose of 0.4&#x000a0;&#x000b5;g/kg/h. For patients aged &#x0003c;60 years, MDZ 2&#x000a0;mg and BPN 0.2&#x000a0;mg were administered, while those aged &#x02265;60 years received a bolus of MDZ 1&#x000a0;mg and BPN 0.1&#x000a0;mg (Table&#x000a0;<xref rid="deo270045-tbl-0002" ref-type="table">2</xref>). The target sedation depth was defined as a Richmond agitation&#x02010;sedation scale (RASS)<xref rid="deo270045-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> of &#x02212;2 to &#x02212;4. During sedation, patients exhibiting movement, sustained blood pressure below 80&#x000a0;mmHg, persistent bradycardia of approximately 40&#x000a0;bpm, airway obstruction, or respiratory arrest were promptly managed appropriately (Table&#x000a0;<xref rid="deo270045-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="deo270045-sec-0100"><title>Monitoring of patients</title><p>During ESD, the blood pressure, pulse, SpO<sub>2</sub>, electrocardiogram, and respiratory rate were monitored. Blood pressure was recorded every 5&#x000a0;min. Oxygen was administered at 2 L/min via a nasal cannula at the initiation of sedation and increased if SpO<sub>2</sub> dropped to &#x02264;93%.</p></sec><sec id="deo270045-sec-0110"><title>Exit criteria</title><p>After endoscopic treatment, DEX was discontinued, and flumazenil, an MDZ antagonist, was administered. The following criteria had to be met before the patient was allowed to leave the recovery area: 1) patient could respond to their name, 2) SpO<sub>2</sub> &#x02265;94% (nasal cannula with oxygen flow at 3 L/min was permissible), 3) no seesaw breathing and a respiratory rate between 10 and 25 breaths/min, 4) systolic blood pressure within 80&#x02013;170&#x000a0;mmHg and pulse rate of 50&#x02013;110 beats/min, and 5) no safety concerns.</p></sec><sec id="deo270045-sec-0120"><title>Statistical analysis</title><p>All statistical analyses were performed using SPSS, version 27 (SPSS Japan Inc.). The results of the OJT scoring by anesthesiologists were statistically analyzed using the Mann&#x02013;Whitney <italic toggle="yes">U</italic> test for each evaluation item. All <italic toggle="yes">p</italic>&#x02010;values were two&#x02010;sided, and a <italic toggle="yes">p</italic>&#x02010;value &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="deo270045-sec-0130"><title>RESULTS</title><p>ESD procedures for upper gastrointestinal tumors were performed on 612 patients between January 2021 and August 2023. Among these, 318 patients received sedation administered by licensed non&#x02010;anesthesiologists. Sedation with DEX and MDZ was used in 238 patients, while propofol and MDZ were used in 80 patients. On the other hand, 294 patients received sedation administered by non&#x02010;licensed non&#x02010;anesthesiologists. Sedation with propofol and MDZ was used in 165 patients, 129 patients were sedated with DEX and MDZ according to sedation regimen with OJT. Sixty&#x02010;eight patients with first, second, and third OJT scoring results were included in the analysis (Figure&#x000a0;<xref rid="deo270045-fig-0002" ref-type="fig">2</xref>). These cases included 14, 52, and two lesions of superficial esophageal cancer, early gastric cancer, and gastric adenoma, respectively. Of the 24 physicians who performed the ESD procedures, eight were gastrointestinal endoscopists, whereas 16 were non&#x02010;specialists.</p><fig position="float" fig-type="FIGURE" id="deo270045-fig-0002"><label>FIGURE 2</label><caption><p>Flowchart</p><p>318 patients received sedation administered by licensed non&#x02010;anesthesiologists. Sedation with DEX and MDZ was used in 238 patients. 294 patients received sedation administered by non&#x02010;licensed non&#x02010;anesthesiologists. 129 patients were sedated with DEX and MDZ according to the sedation regimen with OJT. Sixty&#x02010;eight patients with first, second, and third OJT scoring results were included in the analysis.</p><p>ESD, endoscopic submucosal dissection; DEX, dexmedetomidine; MDZ, midazolam; OJT, on&#x02010;the&#x02010;job training.</p></caption><graphic xlink:href="DEO2-5-e70045-g002" position="anchor" id="jats-graphic-3"/></fig><p>The median age of the patients was 74 (range, 53&#x02013;91) years for superficial esophageal cancer and 75 (range, 35&#x02013;86) years for early gastric cancer and gastric adenoma (Table&#x000a0;<xref rid="deo270045-tbl-0004" ref-type="table">4</xref>). The median BMI was 23.0&#x000a0;kg/m<sup>2</sup> in patients with superficial esophageal cancer and 23.3&#x000a0;kg/m<sup>2</sup> in those with early gastric cancer and gastric adenoma. None of the patients had a BMI &#x0003e;35&#x000a0;kg/m<sup>2</sup>. No patients with COPD were treated with home oxygen therapy. All ESD procedures for superficial esophageal cancer, early gastric cancer, and gastric adenoma were completed. The en&#x02010;bloc resection rate was 92.2% (13/14) for superficial esophageal cancer and 100% (54/54) for early gastric cancer and gastric adenoma. The median treatment duration was 68 (range, 40&#x02013;142) min for superficial esophageal cancer and 84 (range, 24&#x02013;208) min for early gastric cancer and gastric adenoma.</p><table-wrap position="float" id="deo270045-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Clinicopathological characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Superficial esophageal cancer (<italic toggle="yes">n</italic> = 14)</th><th align="left" rowspan="1" colspan="1">Early gastric cancer and gastric adenoma (<italic toggle="yes">n</italic> = 54)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Median (range; years)</td><td align="left" rowspan="1" colspan="1">74 (53&#x02013;91)</td><td align="left" rowspan="1" colspan="1">75 (35&#x02013;86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Male/female</td><td align="left" rowspan="1" colspan="1">13/1</td><td align="left" rowspan="1" colspan="1">43/11</td></tr><tr><td align="left" rowspan="1" colspan="1">Body Mass Index</td><td align="left" rowspan="1" colspan="1">Median (range; kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">23.0 (18.9&#x02013;27.4)</td><td align="left" rowspan="1" colspan="1">23.3 (16.4&#x02013;34.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">ECOG Performance Status</td><td align="left" rowspan="1" colspan="1">0/1</td><td align="left" rowspan="1" colspan="1">13/1</td><td align="left" rowspan="1" colspan="1">42/12</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA physical status</td><td align="left" rowspan="1" colspan="1">I, II/III</td><td align="left" rowspan="1" colspan="1">12/2</td><td align="left" rowspan="1" colspan="1">39/15</td></tr><tr><td align="left" rowspan="1" colspan="1">Charlson comorbidity index</td><td align="left" rowspan="1" colspan="1">0,1/&#x02265;2</td><td align="left" rowspan="1" colspan="1">8/6</td><td align="left" rowspan="1" colspan="1">37/17</td></tr><tr><td align="left" rowspan="1" colspan="1">CPAP use for sleep apnea syndrome</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">2/12</td><td align="left" rowspan="1" colspan="1">3/51</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardio&#x02010;cerebral vascular disease or respiratory disease</td><td align="left" rowspan="1" colspan="1">Positive/negative</td><td align="left" rowspan="1" colspan="1">2/12</td><td align="left" rowspan="1" colspan="1">11/43</td></tr><tr><td align="left" rowspan="1" colspan="1">Antithrombotic drugs</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">5/9</td><td align="left" rowspan="1" colspan="1">18/36</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, pack&#x02010;years</td><td align="left" rowspan="1" colspan="1">Never/light, &#x0003c;30 and heavy, &#x02265;30</td><td align="left" rowspan="1" colspan="1">1/5/8</td><td align="left" rowspan="1" colspan="1">23/13/18</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcoholic intake</td><td align="left" rowspan="1" colspan="1">Never/current/habitual drinker</td><td align="left" rowspan="1" colspan="1">1/11/2</td><td align="left" rowspan="1" colspan="1">17/33/4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pure ethanol equivalent (current or habitual)</td><td align="left" rowspan="1" colspan="1">&#x02265;60&#x000a0;g/&#x0003c;60 g</td><td align="left" rowspan="1" colspan="1">2/12</td><td align="left" rowspan="1" colspan="1">1/36</td></tr><tr><td align="left" rowspan="2" colspan="1">Location</td><td align="left" rowspan="1" colspan="1">Ut/Mt/Lt/Ae (Esophagus)</td><td align="left" rowspan="1" colspan="1">0/11/3</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">U/M/L/remnant (Stomach)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">13/17/21/2</td></tr><tr><td align="left" rowspan="1" colspan="1">Macroscopic type</td><td align="left" rowspan="1" colspan="1">Protruded/flat and depressed</td><td align="left" rowspan="1" colspan="1">4/10</td><td align="left" rowspan="1" colspan="1">22/32</td></tr><tr><td align="left" rowspan="1" colspan="1">Scar</td><td align="left" rowspan="1" colspan="1">Positive/negative</td><td align="left" rowspan="1" colspan="1">0/14</td><td align="left" rowspan="1" colspan="1">1/53</td></tr><tr><td align="left" rowspan="2" colspan="1">Histopathological type</td><td align="left" rowspan="1" colspan="1">SCC/adenocarcinoma (esophagus)</td><td align="left" rowspan="1" colspan="1">11/3</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Differentiated/un&#x02010;differentiated /adenoma/others*(stomach)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">47/3/2/2</td></tr><tr><td align="left" rowspan="1" colspan="1">Diameter of resected specimen Length</td><td align="left" rowspan="1" colspan="1">Median (range; mm)</td><td align="left" rowspan="1" colspan="1">28 (18&#x02013;45)</td><td align="left" rowspan="1" colspan="1">36 (15&#x02013;70)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diameter of resected tumor length</td><td align="left" rowspan="1" colspan="1">Median (range; mm)</td><td align="left" rowspan="1" colspan="1">11 (2&#x02013;35)</td><td align="left" rowspan="1" colspan="1">13 (3&#x02010;45)</td></tr><tr><td align="left" rowspan="2" colspan="1">Depth of invasion</td><td align="left" rowspan="1" colspan="1">EP/LPM or SMM/MM/SM1/SM2</td><td align="left" rowspan="1" colspan="1">6/6/1/1/0</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">M/SM1/SM2</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">45/4/3</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete en block resection</td><td align="left" rowspan="1" colspan="1">% (<italic toggle="yes">n</italic>)</td><td align="left" rowspan="1" colspan="1">92.9 (13/14)</td><td align="left" rowspan="1" colspan="1">100 (54/54)</td></tr><tr><td align="left" rowspan="1" colspan="1">Criteria for curability of endoscopic resection (stomach)</td><td align="left" rowspan="1" colspan="1">eCura A/eCura B/eCura C&#x02010;2</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">44/2/5</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment duration</td><td align="left" rowspan="1" colspan="1">Median (range; min)</td><td align="left" rowspan="1" colspan="1">68 (40&#x02013;142)</td><td align="left" rowspan="1" colspan="1">84 (24&#x02013;208)</td></tr></tbody></table><table-wrap-foot><fn id="deo270045-tbl4-note-0001"><p>
<italic toggle="yes">Note</italic>: CPAP, continuous positive airway pressure; ECOG, Eastern Cooperative Oncology Group; others*, neuroendocrine tumor G1</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The median total dose of DEX was 100 (range 52&#x02013;260) &#x000b5;g. The median total dose of MDZ was 2 (range, 1&#x02013;7) mg, with additional MDZ administered to 53 patients (77.9%). The median total dose of BPN was 0.2 (range, 0.1&#x02013;0.3) mg, and additional BPN was administered to 42 patients (61.8%; Table&#x000a0;<xref rid="deo270045-tbl-0005" ref-type="table">5</xref>).</p><table-wrap position="float" id="deo270045-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Total infusion dose of dexmedetomidine, midazolam, and buprenorphine hydrochloride.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 68</th><th align="left" rowspan="1" colspan="1">
<p>Superficial esophageal cancer</p>
<p>(<italic toggle="yes">n</italic> = 14)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Early gastric cancer and gastric adenoma</p>
<p>(<italic toggle="yes">n</italic> = 54)</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total dose of DEX</td><td align="left" rowspan="1" colspan="1">Median (range) &#x000b5;g</td><td align="left" rowspan="1" colspan="1">100 (52&#x02013;260)</td><td align="left" rowspan="1" colspan="1">100 (60&#x02013;168)</td><td align="left" rowspan="1" colspan="1">96 (52&#x02013;260)</td><td align="left" rowspan="1" colspan="1">0.933</td></tr><tr><td align="left" rowspan="1" colspan="1">Total dose of MDZ</td><td align="left" rowspan="1" colspan="1">Median (range), mg</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;7)</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;6)</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;7)</td><td align="left" rowspan="1" colspan="1">0.821</td></tr><tr><td align="left" rowspan="2" colspan="1">Additional dose of MDZ</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">53 (77.9%)/15 (22.1%)</td><td align="left" rowspan="1" colspan="1">10 (71.4%)/4 (28.6%)</td><td align="left" rowspan="1" colspan="1">43(79.6%)/11(21.4%)</td><td align="left" rowspan="1" colspan="1">0.513</td></tr><tr><td align="left" rowspan="1" colspan="1">Median (range), mg</td><td align="left" rowspan="1" colspan="1">1.5 (1&#x02013;6)</td><td align="left" rowspan="1" colspan="1">1.5 (1&#x02013;4)</td><td align="left" rowspan="1" colspan="1">1 (1&#x02013;6)</td><td align="left" rowspan="1" colspan="1">0.906</td></tr><tr><td align="left" rowspan="1" colspan="1">Total dose of BPN</td><td align="left" rowspan="1" colspan="1">Median (range), mg</td><td align="left" rowspan="1" colspan="1">0.2 (0.1&#x02013;0.3)</td><td align="left" rowspan="1" colspan="1">0.2 (0.1&#x02013;0.3)</td><td align="left" rowspan="1" colspan="1">0.2 (0.1&#x02013;0.3)</td><td align="left" rowspan="1" colspan="1">0.314</td></tr><tr><td align="left" rowspan="2" colspan="1">Additional dose of BPN</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">42 (61.8%)/26 (38.2%)</td><td align="left" rowspan="1" colspan="1">6 (42.9%)/8 (57.1%)</td><td align="left" rowspan="1" colspan="1">36(66.7%)/18 (33.3%)</td><td align="left" rowspan="1" colspan="1">0.105</td></tr><tr><td align="left" rowspan="1" colspan="1">Median (range), mg</td><td align="left" rowspan="1" colspan="1">0.1 (0.1&#x02013;0.2)</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">0.1 (0.1&#x02013;0.2)</td><td align="left" rowspan="1" colspan="1">0.078</td></tr></tbody></table><table-wrap-foot><fn id="deo270045-tbl5-note-0001"><p>Abbreviations: BPN, buprenorphine; DEX, dexmedetomidine; MDZ, midazolam</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>One case of superficial esophageal cancer experienced an intraoperative perforation (7.1%). Among cases of early gastric cancer and gastric adenoma, nine adverse events (16.7%) occurred, including five cases (9.3%) of delayed bleeding, one case (1.9%) of intraoperative perforation, one case (1.9%) of delayed perforation, and two cases (3.7%) of aspiration pneumonia. None of the patients experienced serious adverse events, and all were managed conservatively.</p><p>SpO<sub>2</sub> levels &#x0003c;90% were observed in one patient (1.5%), but oxygenation was improved with supplemental oxygenation. Airway stenosis occurred in one patient (1.5%), which improved after the endoscope was removed without the need for a nasal airway tube, though the procedure was interrupted. This patient had an ASA&#x02010;PS score of 3, a Charlson Comorbidity Index score of 4, a history of renal dysfunction, and a history of heavy alcohol drinking, which may have contributed to oversedation.</p><p>A drop in blood pressure was observed in 30 patients (44.1%), with 27 patients (39.7%) experiencing a decrease of &#x02265;30% from baseline. Bradycardia occurred in 30 patients (44.1%). The frequency of blood pressure decrease and a &#x02265;30% drop in blood pressure compared to baseline was significantly higher in patients with early gastric cancer and gastric adenoma compared to those with superficial esophageal cancer (<italic toggle="yes">p</italic> = 0.012, <italic toggle="yes">p</italic> = 0.030). Ephedrine hydrochloride and atropine sulfate were administered to 32 (47.1%) and 16 (23.5%) patients, respectively. No treatment interruptions occurred due to patient movement. None of the patients experienced serious adverse events that were not improved with the use of ephedrine hydrochloride or atropine sulfate (Table&#x000a0;<xref rid="deo270045-tbl-0006" ref-type="table">6</xref>).</p><table-wrap position="float" id="deo270045-tbl-0006" content-type="TABLE"><label>TABLE 6</label><caption><p>Safety of sedation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> = 68</th><th align="left" rowspan="1" colspan="1">
<p>Superficial esophageal cancer</p>
<p>(<italic toggle="yes">n</italic> = 14)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Early gastric cancer and gastric adenoma</p>
<p>(<italic toggle="yes">n</italic> = 54)</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Body movement to the extent that treatment is interrupted</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">0 (0%)/68 (100%)</td><td align="left" rowspan="1" colspan="1">0 (0%)/14 (100%)</td><td align="left" rowspan="1" colspan="1">0 (0%)/54 (100%)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased oxygen*</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">13 (19.1%)/55 (80.9%)</td><td align="left" rowspan="1" colspan="1">1 (7.1%)/13 (92.9%)</td><td align="left" rowspan="1" colspan="1">12 (22.2%)/42 (77.8%)</td><td align="left" rowspan="1" colspan="1">0.204</td></tr><tr><td align="left" rowspan="1" colspan="1">Maximum oxygen flow rate</td><td align="left" rowspan="1" colspan="1">Median (range), (L/min)</td><td align="left" rowspan="1" colspan="1">2 (2&#x02013;10)</td><td align="left" rowspan="1" colspan="1">2 (2&#x02013;4)</td><td align="left" rowspan="1" colspan="1">2 (2&#x02013;10)</td><td align="left" rowspan="1" colspan="1">0.219</td></tr><tr><td align="left" rowspan="1" colspan="1">SpO2 (minimum value during treatment)</td><td align="left" rowspan="1" colspan="1">Median (range), (%)</td><td align="left" rowspan="1" colspan="1">97 (88&#x02013;100)</td><td align="left" rowspan="1" colspan="1">98 (94&#x02013;99)</td><td align="left" rowspan="1" colspan="1">97(88&#x02013;100)</td><td align="left" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">SpO2 &#x0003c;90% (minimum value during treatment)</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">1 (1.9%)</td><td align="left" rowspan="1" colspan="1">0.611</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasal airway insertion</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypotension (&#x0003c;90&#x000a0;mmHg)</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30 (44.1%)</td><td align="left" rowspan="1" colspan="1">2 (14.3%)</td><td align="left" rowspan="1" colspan="1">28 (51.9%)</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Drop in blood pressure of &#x02265;30% compared to baseline</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">27 (39.7%)</td><td align="left" rowspan="1" colspan="1">2 (14.3%)</td><td align="left" rowspan="1" colspan="1">25 (46.3%)</td><td align="left" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" rowspan="1" colspan="1">Bradycardia (pulse &#x0003c;50&#x000a0;bpm)</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">30 (44.1%)</td><td align="left" rowspan="1" colspan="1">5 (35.7%)</td><td align="left" rowspan="1" colspan="1">25 (46.3%)</td><td align="left" rowspan="1" colspan="1">0.481</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment was interrupted except for body movement</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">1 (1.5%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">1 (1.9%)</td><td align="left" rowspan="1" colspan="1">0.611</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional doses of haloperidol or flunitrazepam</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">0 (0.0%)/68 (100.0%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Administration of ephedrine hydrochloride</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">32 (47.1%)/36 (52.9%)</td><td align="left" rowspan="1" colspan="1">5 (35.7%)/9 (54.3%)</td><td align="left" rowspan="1" colspan="1">27 (50.0%)/27 (50.0%)</td><td align="left" rowspan="1" colspan="1">0.344</td></tr><tr><td align="left" rowspan="1" colspan="1">Administration of atropine sulfate</td><td align="left" rowspan="1" colspan="1">Yes/no</td><td align="left" rowspan="1" colspan="1">16 (23.5%)/52 (76.5%)</td><td align="left" rowspan="1" colspan="1">4 (28.6%)/10 (71.4%)</td><td align="left" rowspan="1" colspan="1">12 (22.2%)/42 (77.8%)</td><td align="left" rowspan="1" colspan="1">0.620</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>A total of 22 non&#x02010;anesthesiologists, including 14 physicians in their 3rd year, seven in their 5<sup>th</sup> year, and one in their 12<sup>th</sup> year performed sedation. Among them, there was one specialist in gastrointestinal endoscopy and 21 non&#x02010;specialists. All 22 non&#x02010;anesthesiologists passed the proficiency evaluation.</p><p>Figure&#x000a0;<xref rid="deo270045-fig-0003" ref-type="fig">3</xref> shows the scoring results and overall mean values for the 11 evaluation items across the first, second, and third OJT sessions. The overall mean scores for the 11 proficiency items among non&#x02010;anesthesiologists progressively improved from the first to the third OJT session.</p><fig position="float" fig-type="FIGURE" id="deo270045-fig-0003"><label>FIGURE 3</label><caption><p>Scoring results and overall mean values for the 11 evaluation items of the first, second, and third on&#x02010;the&#x02010;job training (OJT) sessions.</p><p>OJT, on&#x02010;the&#x02010;job training.</p></caption><graphic xlink:href="DEO2-5-e70045-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="deo270045-sec-0140"><title>DISCUSSION</title><p>Sedation with DEX and MDZ, administered according to the sedation regimen, was considered feasible, with few instances of airway stenosis or body movement that interrupted the treatment despite some circulatory changes, including hypotension and bradycardia.</p><p>DEX is a selective &#x003b1;2 adrenergic receptor agonist that activates &#x003b1;2A receptors in the nucleus accumbens and spinal cord of the cerebral bridge, providing sedative, analgesic, and sympathoinhibitory effects with minimal respiratory depression.<xref rid="deo270045-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Takimoto et&#x000a0;al. conducted a three&#x02010;arm comparison study on sedation during ESD for early gastric cancer, comparing DEX, MDZ, and propofol. They reported significantly fewer instances of body movement and a decrease in SpO<sub>2</sub> that interrupted treatment in the DEX group compared to the MDZ or propofol groups. They also observed a 17% decrease in blood pressure of &#x02265;30% from baseline, though this was not significantly different from the MDZ and propofol groups.<xref rid="deo270045-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>Yoshio et&#x000a0;al. reported that sedation using DEX and MDZ during ESD for superficial esophageal cancer was beneficial, with less body movement and respiratory depression than MDZ alone, with approximately 90% of endoscopists satisfied with the sedation.<xref rid="deo270045-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, as patients were sedated to deep levels (Ramsay sedation score of 4&#x02013;6) using a DEX loading dose after 3&#x000a0;mg of MDZ and 17.5&#x000a0;mg of pethidine, the incidence of respiratory depression was notably high, affecting 23% of patients. Additionally, 80% of patients experienced respiratory depression within 4&#x000a0;min of treatment initiation.</p><p>In ESD for superficial esophageal cancer, many patients were heavy alcohol consumers, which may reduce the effectiveness of sedation with benzodiazepines, leading to treatment interruptions due to body movements.<xref rid="deo270045-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270045-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> In contrast, in this study, ESD was performed with moderate sedation, targeting a RASS scale of &#x02212;2 to &#x02212;4. Respiratory depression or body movements that interrupted treatment were rare, and all cases were completely resected en bloc. Although hypotension and bradycardia occurred in 44.1% of patients, all patients were treated with ephedrine hydrochloride or atropine sulfate, which is comparable to that in previous reports. Thus, in this study, the sedation regimen was effective in ensuring safe sedation.</p><p>Additionally, an overall increase in the scores and mean values for the 11 proficiency items was noted after three OJT sessions for non&#x02010;anesthesiologists. This suggests that conducting three OJT sessions, rather than two, may enhance the safety and effectiveness of sedation with DEX and MDZ.</p><p>The OJT program was conducted to ensure safety when DEX was introduced for endoscopic procedures. Although the effectiveness of the OJT remains to be fully validated, it is believed that non&#x02010;anesthesiologists acquired essential knowledge about sedation through the web&#x02010;based training program. The introduction of DEX under anesthesiologists' supervision raised awareness of sedation techniques, allowing for its safe administration. The efficacy of OJT will be further evaluated as more cases are included in future studies.</p><p>This study had certain limitations. It was a single&#x02010;center, retrospective, observational study. No randomized controlled trials have compared DEX and MDZ sedation to other sedation methods. Additionally, the presence of an anesthesiologist during the procedures may have influenced the sedation outcomes. Selection bias, from the perspective of clinical practice, also cannot be ruled out. Therefore, our findings should be validated with larger sample sizes and additional clinical studies.</p><p>In Japan, unlike Europe and the United States, assigning anesthesiologists to endoscopic procedures is challenging because of the chronic shortage of anesthesiologist personnel.<xref rid="deo270045-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> To minimize the risk of sedation&#x02010;related incidents by non&#x02010;anesthesiologists, we believe that conducting thorough patient risk assessments, assigning sedation personnel separate from the endoscopist, and establishing clear guidelines are important for sedation protocols.</p><p>In conclusion, a sedation regimen combining DEX and MDZ can be safely administered by non&#x02010;anesthesiologists. However, further validation studies are needed to assess its appropriateness.</p></sec><sec sec-type="COI-statement" id="deo270045-sec-0160"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270045-sec-0170"><title>ETHICS STATEMENT</title><p>The current study adhered to the principles outlined in the Declaration of Helsinki and received approval from the Ethics Committee of the Kitasato University School of Medicine Hospital (B21&#x02010;207).</p></sec><sec id="deo270045-sec-0180"><title>PATIENT CONSENT STATEMENT</title><p>Informed consent (with the option to opt&#x02010;out) was obtained from all patients in compliance with the Japanese guidelines for human medical research.</p></sec><sec id="deo270045-sec-0190"><title>CLINICAL TRIAL REGISTRATION</title><p>N/A.</p></sec></body><back><ack id="deo270045-sec-0150"><title>ACKNOWLEDGMENTS</title><p>The authors acknowledge the help of Masayuki Kuroiwa, M.D., and medical staff at Kitasato University School of Medicine.</p></ack><ref-list id="deo270045-bibl-0001"><title>REFERENCES</title><ref id="deo270045-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270045-cit-0001">
<string-name>
<surname>Cohen</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Delegge</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Aisenberg</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>AGA Institute review of endoscopic sedation</article-title>. <source>Gastroenterology</source>
<year>2007</year>; <volume>133</volume>: <fpage>675</fpage>&#x02013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">17681185</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270045-cit-0002">
<string-name>
<surname>Metzner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Posner</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Domino</surname>
<given-names>KB</given-names>
</string-name>. <article-title>The risk and safety of anesthesia at remote locations: The US closed claims analysis</article-title>. <source>Curr Opin Anaesthesiol</source>
<year>2009</year>; <volume>22</volume>: <fpage>502</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">19506473</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="deo270045-cit-0003">
<collab collab-type="authors">Japanese Society of Anesthesiologists</collab>
<article-title>. Proposal of the Japanese Society of Anesthesiologists for the shortage of anesthesiologist manpower. Accessed: October 2, 2024 (In Japanese)</article-title>. <ext-link xlink:href="https://anesth.or.jp/files/download/news/suggestion20050209_1.pdf" ext-link-type="uri">https://anesth.or.jp/files/download/news/suggestion20050209_1.pdf</ext-link>
</mixed-citation></ref><ref id="deo270045-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270045-cit-0004">
<string-name>
<surname>Early</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Lightdale</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Vargo</surname>
<given-names>JJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Guidelines for sedation and anesthesia in GI endoscopy</article-title>. <source>Gastrointest Endosc</source>
<year>2018</year>; <volume>87</volume>: <fpage>327</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">29306520</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270045-cit-0005">
<string-name>
<surname>Gotoda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Akamatsu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Guidelines for sedation in gastroenterological endoscopy (second edition)</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>21</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">33124106</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270045-cit-0006">
<string-name>
<surname>Inatomi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Imai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Dexmedetomidine is safe and reduces the additional dose of midazolam for sedation during endoscopic retrograde cholangiopancreatography in very elderly patients</article-title>. <source>BMC Gastroenterol</source>
<year>2018</year>; <volume>18</volume>: <fpage>166</fpage>.<pub-id pub-id-type="pmid">30400828</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="deo270045-cit-0007">
<collab collab-type="authors">American Society of Anesthesiologists</collab>
<article-title>. ASA physical status classification system. Accessed: October 2, 2024</article-title>. <ext-link xlink:href="https://www.asahq.org/resources/clinical-information/asaphysicalstatus/classification/system" ext-link-type="uri">https://www.asahq.org/resources/clinical&#x02010;information/asaphysicalstatus/classification/system</ext-link>
</mixed-citation></ref><ref id="deo270045-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270045-cit-0008">
<string-name>
<surname>Charlson</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Pompei</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ales</surname>
<given-names>KL</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation</article-title>. <source>J Chronic Dis</source>
<year>1987</year>; <volume>40</volume>: <fpage>373</fpage>&#x02013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">3558716</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0009"><label>9</label><mixed-citation publication-type="book" id="deo270045-cit-0009">
<collab collab-type="authors">Japanese Gastric Cancer Association</collab>
. <source>Gastric Cancer Treatment Guideline</source>, <edition>6th edn</edition>, <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanehara</publisher-name>, <year>2021</year>.</mixed-citation></ref><ref id="deo270045-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="deo270045-cit-0010">
<collab collab-type="authors">National Cancer Institute</collab>
<article-title>. Common terminology criteria for adverse events (CTCAE). Ver. 5.0. Accessed: October 2, 2024</article-title>. <ext-link xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf" ext-link-type="uri">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf</ext-link>
</mixed-citation></ref><ref id="deo270045-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270045-cit-0011">
<string-name>
<surname>Sessler</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Gosnell</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Grap</surname>
<given-names>MJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The Richmond Agitation&#x02010;Sedation Scale: Validity and reliability in adult intensive care unit patients</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2002</year>; <volume>166</volume>: <fpage>1338</fpage>&#x02013;<lpage>1344</lpage>.<pub-id pub-id-type="pmid">12421743</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270045-cit-0012">
<string-name>
<surname>Hashiguchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matsunaga</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Dexmedetomidine for sedation during upper gastrointestinal endoscopy</article-title>. <source>Dig Endosc</source>
<year>2008</year>; <volume>20</volume>: <fpage>178</fpage>&#x02013;<lpage>183</lpage>.</mixed-citation></ref><ref id="deo270045-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270045-cit-0013">
<string-name>
<surname>Takimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shimamoto</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Sedation with dexmedetomidine hydrochloride during endoscopic submucosal dissection of gastric cancer</article-title>. <source>Dig Endosc</source>
<year>2011</year>; <volume>23</volume>: <fpage>176</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">21429025</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270045-cit-0014">
<string-name>
<surname>Yoshio</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ishiyama</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tsuchida</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma</article-title>. <source>Esophagus</source>
<year>2019</year>; <volume>16</volume>: <fpage>285</fpage>&#x02013;<lpage>291</lpage>.<pub-id pub-id-type="pmid">30937573</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270045-cit-0015">
<string-name>
<surname>Lieber</surname>
<given-names>CS</given-names>
</string-name>. <article-title>Alcohol and the liver: 1994 update</article-title>. <source>Gastroenterology</source>
<year>1994</year>; <volume>106</volume>: <fpage>1085</fpage>&#x02013;<lpage>1105</lpage>.<pub-id pub-id-type="pmid">8143977</pub-id>
</mixed-citation></ref><ref id="deo270045-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270045-cit-0016">
<string-name>
<surname>Weathermon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Crabb</surname>
<given-names>DW</given-names>
</string-name>. <article-title>Alcohol and medication interactions</article-title>. <source>Alcohol Res Health</source>
<year>1999</year>; <volume>23</volume>: <fpage>40</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">10890797</pub-id>
</mixed-citation></ref></ref-list></back></article>